Skip to main content
. 2017 Aug 2;8(39):66033–66050. doi: 10.18632/oncotarget.19789

Figure 1. Effects of oxysterols and transporter inhibitors on the cell-killing effect of doxorubicin in breast cancer cells.

Figure 1

Cell growth was monitored by measuring mitochondrial MTT reduction activity. Panel (A) shows the cell-killing effects of increasing concentrations of doxorubicin in MCF-7, MB-231, and MCF-7/ADR cells. Panel (B) shows the alterations of the cell-killing effect of doxorubicin by hydroxycholesterols (HCs) in MCF-7 cells. Panels (C) and (D) show the alterations of the cell-killing effect of doxorubicin by 7-ketocholesterol (7-KC) and transporter inhibitors in MCF-7 and MB-231 cells, respectively. Cells were exposed to oxysterols and transporter inhibitors for 24 h prior to the co-exposure to 3 μM doxorubicin and respective oxysterols for a further 24 h. The exposure concentrations of transporter inhibitors were 10 μM verapamil (V), 5 μM indomethacin (I), and 1 μM fumitremorgin C (F). The results are presented as means ± SD of three independent experiments with three determinations within each experiment. n.s.: There was no significant difference compared to the control vehicle exposure or cells without the exposure to inhibitors. *p < 0.05, compared to the vehicle control. #p < 0.05, compared to the doxorubicin-treated cells or the comparison between two treatments as indicated.